Multimeric Biotherapeutics, Inc.
Multimeric Biotherapeutics, Inc. is a biotechnology company based in San Diego, focused on developing immunotherapies and vaccines against infectious diseases and cancer. They are developing the FortiVac platform, which elicits strong CD8+ T cell responses for anti-viral and tumor immunotherapy. The company aims to address unmet medical needs in cancer and infectious disease vaccination, leveraging patented vaccine platform technology that enhances immune responses, particularly CD8+ T cell responses.
Industries
Nr. of Employees
small (1-50)
Multimeric Biotherapeutics, Inc.
Products
Multimeric fusion-protein vaccine platform
A vaccine platform based on self-assembling multimeric fusion proteins that combine a TNF superfamily ligand extracellular domain, a multimerization scaffold, and antigen sequences to target dendritic cells and elicit high-level CD8+ T cell responses for applications in infectious disease and cancer.
Multimeric fusion-protein vaccine platform
A vaccine platform based on self-assembling multimeric fusion proteins that combine a TNF superfamily ligand extracellular domain, a multimerization scaffold, and antigen sequences to target dendritic cells and elicit high-level CD8+ T cell responses for applications in infectious disease and cancer.
Expertise Areas
- Vaccine platform development
- T-cell immunology focused on CD8+ responses
- Fusion protein engineering and multimerization scaffolds
- Preclinical murine efficacy and challenge models
Key Technologies
- Multimeric fusion proteins
- CD40 receptor-targeted antigen delivery
- Self-assembling protein scaffolds derived from surfactant protein D-like domains
- Adenoviral vector expression